Home › Research › Prevention and risk
Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death
Marc Humbert, Vallerie V. McLaughlin, David B. Badesch, Hossein Ardeschir Ghofrani, J. Simon R. Gibbs, Mardi Gomberg‐Maitland, Ioana R. Preston, Rogério Souza et al.. New England Journal of Medicine, 2025-05-28
Topic: Brain proteins, microglia and lab models
Plain-language summary
A total of 172 patients were included (86 each in the sotatercept and placebo groups). The trial was stopped early on the basis of the efficacy results of a prespecified interim analysis. At least one primary end-point event occurred in 15 patients (17.4%) in the sotatercept group and in 47 patients (54.7%) in the placebo group (hazard ratio, 0.24; 95% confidence interval, 0.13 to 0.43; P<0.001). Death from any cause occurred in 7 patients (8.1%) in the sotatercept group and in 13 patients (15.1%) in the placebo group; lung transplantation in 1 patient (1.2%) and 6 patients (7.0%), respectively; and hospitalization for worsening pulmonary arterial hypertension in 8 patients (9.3%) and 43 patients (50.0%). The most common adverse events with sotatercept were epistaxis and telangiectasia. Among high-risk adults with pulmonary arterial hypertension who were receiving the maximum tolerated dose of background therapy, treatment with sotatercept resulted in a lower risk of a composite of death from any cause, lung transplantation, or hospitalization (≥24 hours) for worsening pulmonary arterial hypertension than placebo. (Funded by Merck Sharp and Dohme, a subsidiary of Merck [Rahway, NJ]; ZENITH ClinicalTrials.gov number, NCT04896008.).
What this study adds
Evidence grade: Low
This is a trial of 172 participants. This trial tested sotatercept in adults with pulmonary arterial hypertension at high risk of death, not Alzheimer's disease. Reported effect size: 17.4%; 54.7%; 8.1%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Humbert, M., McLaughlin, V. V., Badesch, D. B., Ghofrani, H. A., Gibbs, J. S. R., Gomberg‐Maitland, M., et al. (2025). Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2415160
Vancouver
Humbert M, McLaughlin VV, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg‐Maitland M, et al. Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. New England Journal of Medicine. 2025. doi:10.1056/nejmoa2415160. PMID: 40167274.
BibTeX
@article{humbert2025-40167274,
author = {Humbert, Marc and McLaughlin, Vallerie V. and Badesch, David B. and Ghofrani, Hossein Ardeschir and Gibbs, J. Simon R. and Gomberg‐Maitland, Mardi and Preston, Ioana R. and Souza, Rogério and others},
title = {{Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death}},
journal = {New England Journal of Medicine},
year = {2025},
doi = {10.1056/nejmoa2415160},
pmid = {40167274},
url = {https://doi.org/10.1056/nejmoa2415160}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- A total of 172 patients were included (86 each in the sotatercept and placebo groups).
- The trial was stopped early on the basis of the efficacy results of a prespecified interim analysis.
- At least one primary end-point event occurred in 15 patients (17.4%) in the sotatercept group and in 47 patients (54.7%) in the placebo group (hazard ratio, 0.24; 95% confidence interval, 0.13 to 0.43; P<0.001).
- Death from any cause occurred in 7 patients (8.1%) in the sotatercept group and in 13 patients (15.1%) in the placebo group; lung transplantation in 1 patient (1.2%) and 6 patients (7.0%), respectively; and hospitalization for worsening pulmonary arterial hypertension in 8 patients (9.3%) and 43 patients (50.0%).
- The most common adverse events with sotatercept were epistaxis and telangiectasia.
Why it matters
This trial tested sotatercept in adults with pulmonary arterial hypertension at high risk of death, not Alzheimer's disease. It found sotatercept lowered the risk of death, lung transplantation or hospitalization for worsening pulmonary arterial hypertension compared with placebo, and the trial was stopped early for efficacy.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Study designclinical trial
- Participants172
- Effect size17.4%; 54.7%; 8.1%
- Evidence strengthLow
How this study scored 67/100
Published in a top-tier journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (New England Journal of Medicine) |
| Journal's citation record | 4 / 4 | New England Journal of Medicine: journal h-index 1,505 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 172 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 160 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 53.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 6 / 6 | Cited 97.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 3 / 4 | Cited 160 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Marius M. Hoeper: h-index 122 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 25 institution(s) in 6 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40167274) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 67 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Prevention and risk from nearby years
Also in Prevention and risk
269 studies in the library are filed under Prevention and risk with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Prevention and risk hub.